AMG 780 / Amgen, Takeda - LARVOL DELTA

Angiopoietin inhibitors: A review on targeting tumor angiogenesis. (PubMed, Eur J Pharmacol) - "Drugs studied in the article are selective as well as non-selective inhibitors of angiopoietin 2 like Trebananib (AMG 386), AMG 780, REGN 910, CVX 060, MEDI 3617 and dual inhibitors of angiopoietin 2 and VEGF like Vanucizumab and RG7716. The angiopoietin inhibitors show promising results alone and in combination with VEGF inhibitors in various malignancies."

Journal • Review • Immunology • Inflammation • Oncology

A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors (ASCO 2014) - Presentation time: Sunday, Jun 1; 8:00 AM - 11:45 AM; Abstract #2542; P1, N=44; Sponsor: Amgen; NCT01137552; "Of 31 evaluable pts, six pts had stable disease (SD); one pt had SD lasting > 6 months. Twenty pts had progressive disease. Of 16 pts with DCE-MRI data, Ktrans for 6 pts and IAUC for 5 pts decreased > 20% at week 5 postdose relative to baseline"

P1 data • Oncology